Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective observational study of the long term hazards of biologic therapy in rheumatoid arthritis.

Trial Profile

Prospective observational study of the long term hazards of biologic therapy in rheumatoid arthritis.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Infliximab (Primary) ; Rituximab (Primary) ; Tocilizumab (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms BSRBR-RA
  • Most Recent Events

    • 24 Oct 2018 Results (n=1177) presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 28 Mar 2018 Results (n=19282) assessing rate of serious infections published in the Annals of the Rheumatic Diseases
    • 17 Jun 2017 Preliminary results (n= 417) presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top